# US 2006/0078606 A1 · Sustained-release liposomal anesthetic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078606 A1
- Document ID: US20060078606A1
- Status: Published application
- Kind: A1
- Application number: 11/097,756
- Filed: 2005-04-01
- Published: 2006-04-13
- Earliest claimed: 1997-09-18
- Assignees: SkyePharma Inc.
- Inventors: Sinil Kim; Taehee Kim; Sharad Murdande
- Web page: https://patentgrep.com/patent/US20060078606A1

## CPC

- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 23/02: Local anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A pharmaceutical composition comprising:
a) a multivesicular liposome comprising at least one amphipathic lipid, and at least one neutral lipid; and
b) an aqueous phase comprising a salt of an amide anesthetic selected from the group consisting of polyhydroxy carboxylate, diprotic mineral, triprotic mineral, and combinations thereof;
wherein the aqueous phase is encapsulated within the multivesicular liposome.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the aqueous phase further comprises hydrochloric acid.

### Claim 25 (depends on 23)

The pharmaceutical composition of claim 23, wherein the amphipathic lipid is provided in admixture with cholesterol, plant sterols, or combinations thereof.

### Claim 26 (depends on 23)

The pharmaceutical composition of claim 23, wherein the mineral salt of the amide anesthetic is selected from the group consisting of sulfates, phosphates and combinations thereof.

### Claim 27 (depends on 23)

The pharmaceutical composition of claim 23, wherein the polyhydroxy carboxylate salt of the amide anesthetic is selected from the group consisting of glucuronate, gluconate, tartarate and combinations thereof.

### Claim 28 (depends on 23)

The pharmaceutical composition of claim 23, wherein the amphipathic lipid is selected form the group consisting of phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, lysophosphatidylcholines, lysophosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, phosphatidic acids, cardiolipins, diacyl dimethylammonium propanes, stearyl amines, and combinations thereof.

### Claim 29 (depends on 23)

The pharmaceutical composition of claim 23, wherein the neutral lipid is selected from the group consisting of triglycerides, diglycerides, ethylene glycol, esters, squalene and combinations thereof.

### Claim 30 (depends on 23)

The pharmaceutical composition of claim 23, wherein the amide anesthetic is xylidide.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the xylidide is selected form the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine, their stereoisomers and combinations thereof.

### Claim 32 (depends on 8)

The pharmaceutical composition of claim 8, wherein the xylidide has the following structure:
wherein R1 is a secondary or tertiary alkyl amine or a secondary or tertiary alkylene amine, R2 is hydrogen, alkyl or alkylene which further links to R1, R3 is an alkyl substituted phenyl substituent.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein R1 and R2 form a substituent selected from the group consisting of N-alkyl piperadine and N-alkyl pyrrolidine.

### Claim 34 (depends on 32)

The pharmaceutical composition of claim 32, wherein R3 is 2,6-dimethylphenyl substituent.

### Claim 35

A process for preparing a multivesicular liposome-encapsulated anesthetic composition, the process comprising:
a) forming a “water-in-oil” emulsion from a first aqueous phase and a volatile organic phase, wherein the first aqueous phase comprises a salt of an amide anesthetic selected from the group consisting of polyhydroxy carboxylate, diprotic mineral, triprotic mineral, and combinations thereof, and wherein the volatile organic phase comprises
a volatile organic solvent,
at least one amphipathic lipid, and at least one neutral lipid;
b) dispersing the “water-in-oil” emulsion into a second aqueous phase to form solvent spherules; and
c) removing the volatile organic solvent from the solvent spherules to form a multivesicular liposome-encapsulated amide anesthetic suspended in the aqueous phase.

### Claim 36 (depends on 35)

The process of claim 35, wherein the amide anesthetic is a xylidide.

### Claim 37 (depends on 36)

The process of claim 36, wherein the xylidide is selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine, their stereoisomers and combinations thereof.

### Claim 38 (depends on 23)

A method of locally anesthetizing a subject, the method comprising administering the pharmaceutical composition of claim 23.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition comprises a xylidide.

### Claim 40 (depends on 39)

The method of claim 39, wherein the xylidide is selected form the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine, their stereoisomers and combinations thereof.

### Claim 41

A method of increasing drug loading in a multivesicular liposome by converting an amide anesthetic into a binary salt mixture wherein two counterions are derived from an acid selected from the group consisting of polyhydroxy carboxylic, diprotic mineral, triprotic mineral, and combinations thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the polyhydroxy carboxylic acid is selected from the group consisting of sulfuric acid, phosphoric acid, and combinations thereof.

### Claim 43 (depends on 41)

The method of claim 41, wherein the mineral acid is selected from the group consisting of glucuronic acid, gluconic acid, tartaric and combinations thereof.

### Claim 44 (depends on 41)

The method of claim 41, wherein the amide anesthetic is a xylidide selected from the group consisting of bupivacaine, mepivacaine, ropivacaine, lidocaine, pyrrocaine, prilocaine, their stereoisomers and combinations thereof.
